Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects (11-17 years of age inclusive) who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment~* who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period)~* in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.~Exclusion Criteria:~* History of any serogroup B meningococcal vaccination~* Current or previous, confirmed or suspected disease caused by N. meningitidis~* Exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment~* Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38.0 °C) within the previous day~* Antibiotic use within 3 days (72 hours) prior to enrollment~* Pregnancy or nursing (breastfeeding) mothers~* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry~* Any serious chronic or progressive disease, Known or suspected impairment/alteration of the immune system~* Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days~* History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- MenB Lot 1 (Type: EXPERIMENTAL): MenB vaccine Lot 1: 2 doses administered 1 month apart
- MenB Lot 2 (Type: ACTIVE_COMPARATOR): MenB vaccine Lot 2: 2 doses administered 1 month apart

Based on this trial design, predict the completion outcome and termination type (if applicable).